Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Kristin Scoggins

Pulmonary Disease Jackson, MS Nurse Practitioner

NPI 1114789781 CMS profile 11639069

501 Marshall St Ste 200, Jackson, MS 39202

Open in the dashboard

General payments

$3,719

194 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristin Scoggins of Jackson, MS is reported in the CMS Open Payments database as having received $3,719 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,360 131
2024 General $1,358 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristin Scoggins
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Kristin Scoggins were reported at $2,360. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Kristin Scoggins Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $1,358 $476 $123–$1,818 $164
2025 $2,360 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AstraZeneca Pharmaceuticals LP $884 40 payments
  2. Mallinckrodt Hospital Products Inc. $548 23 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $373 20 payments
  4. GlaxoSmithKline, LLC. $293 16 payments
  5. Verona Pharma, Inc. $269 25 payments
  6. Genzyme Corporation $249 13 payments
  7. Merck Sharp & Dohme Corporation $202 10 payments
  8. Mylan Specialty L.P. $185 11 payments
  9. Regeneron Healthcare Solutions, Inc. $154 6 payments
  10. Viatris Specialty LLC $143 10 payments
  11. Other $419 20 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $3,719 194 payments
Products named General payments · program years 2024–2025
  1. ACTHAR $548 23 payments
  2. YUPELRI $329 21 payments
  3. FASENRA $320 13 payments
  4. AIRSUPRA $273 13 payments
  5. Ohtuvayre $269 25 payments
  6. DUPIXENT $249 13 payments
  7. OFEV $245 13 payments
  8. TEZSPIRE $226 6 payments
  9. BREZTRI $196 10 payments
  10. NUCALA $154 8 payments
  11. Other $1,143 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

90

Median for Nurse Practitioner: 389

Drug cost

$13,065

Median for Nurse Practitioner: $21,885

Branded share of claims

73.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $11,547
Albuterol Sulfate Hfa Albuterol Sulfate Brand 49 $1,436
Pantoprazole Sodium Generic 24 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$8,869

Medicare's payments for the services billed

Medicare patients

68

Average age 75

Services billed

241

48 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 57%
Arthritis 54%
Ischemic heart disease 38%
Depression 34%
Chronic kidney disease 32%
Heart failure 28%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $173
  • Amgen Inc. $19
$193 — —
YUPELRI
  • Mylan Specialty L.P. $185
$185 — —
DUPIXENT
  • GENZYME CORPORATION $79
  • Regeneron Healthcare Solutions, Inc. $69
$149 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $138
$138 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $131
$131 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record